rf IDEAS celebrates 25 years of identity access management innovation.
30.4.2020 23:48:00 EEST | Business Wire | Press release
As a leader in the identity access management industry, rf IDEAS welcomes its 25th year in business with a refreshed brand, revamped website, and new products in the WAVE ID® line of proximity and contactless identification, mobile credential and authentication readers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200430006013/en/
WAVE ID® Nano USB-C (Photo: Business Wire)
A tradition of progressive product development and exceptional customer service is demonstrated in long-lasting partnerships with Imprivata, HP, and Google. "Collaboration is the key to our growth and leadership in the identity access management market," says David Cottingham, president of rf IDEAS. "Our new products—including great strides in contactless authentication—reflect our drive to create market solutions that anticipate and deliver on the changing needs of customers."
The redesigned rfIDEAS.com website guides customers to the ideal solution for applications such as employee identification, secure printing, time and attendance, and other areas, with biometric authentication solutions coming soon.
The company’s newest single sign-on solution, WAVE ID® Nano USB-C, delivers the same wireless reader technology now available in the fast-growing Type-C USB connector, in a design that stands up to hostile environments. It makes reader capabilities possible on smaller devices and is compatible with Apple, Google, and Microsoft USB-C enabled devices, clinician laptops, and mobility applications.
The company’s commitment to innovation and quality ensures that all processes, product quality control, development and overall corporate management meet and exceed customer expectations. As a result, rf IDEAS was listed for five consecutive years (2011 through 2015) on Inc. magazine's list of America's Fastest-Growing Private Companies prior to its acquisition in 2015 by Roper Technologies, Inc. New branding and product lines continue to reflect this dedication to thought leadership and innovation.
About rf IDEAS
rf IDEAS, Inc. is a leader in the card and credential reader space for healthcare, manufacturing, government, and enterprise. Partnering with leading technology companies, rf IDEAS readers enable innovative solutions for single sign-on, secure printing, attendance tracking, and other applications that require authentication. rf IDEAS readers support nearly all credential technologies worldwide and the growing set of mobile credentials. For more information, visit www.rfideas.com.
rf IDEAS® is a registered trademark of rf IDEAS, Inc. All other trademarks, service marks and product or service names are property of their respective owners
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200430006013/en/
Contact information
Media Contact
Arlene King
Marketing Manager
Ph: (866) 439-4884 Ext: 480
E: Marketing@RFIDeas.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom